![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
To all interested Biotech investors, please feel free to discuss GENE on this thread. I will put together financial information and additional broker analysis on this stock as time progresses. My broker said that the latest report from a firm that tracks this company projects a price of $25 in 12 months, currently trading at $10 (5/16/96). This company works on genome research to identify and characterize genes involved in common diseases, and to translate the discoveries into therapeutic breakthroughs. GENE is a fast-growing and financially successful biotechnology company. In the past year they have been awarded over US$10M by the NIH to develop state-of-the-art DNA sequencing technology initiated a US$22M alliance with Astra AB to develop genome-based drugs and vaccines entered into a US$40M research collaboration with Schering-Plough Corporation to discover novel anti-infective agents raised US$2.1M in a private capital placement and raised US$44M in a public stock offering Good Luck Tara!!! :) | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |